NASDAQ:NLTX Neoleukin Therapeutics (NLTX) Stock Forecast, Price & News $4.03 +0.12 (+3.07%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$3.90▼$4.1050-Day Range$3.10▼$4.1652-Week Range$1.88▼$4.70Volume55,289 shsAverage Volume58,450 shsMarket Capitalization$35.46 millionP/E RatioN/ADividend YieldN/APrice Target$7.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Neoleukin Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside86.1% Upside$7.50 Price TargetShort InterestHealthy0.12% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.49Based on 6 Articles This WeekInsider TradingAcquiring Shares$1.31 M Bought Last QuarterProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector439th out of 969 stocksPharmaceutical Preparations Industry194th out of 455 stocks 3.0 Analyst's Opinion Consensus RatingNeoleukin Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $7.50, Neoleukin Therapeutics has a forecasted upside of 86.1% from its current price of $4.03.Amount of Analyst CoverageNeoleukin Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.12% of the float of Neoleukin Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeoleukin Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neoleukin Therapeutics has recently decreased by 63.53%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeoleukin Therapeutics does not currently pay a dividend.Dividend GrowthNeoleukin Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NLTX. Previous Next 1.9 News and Social Media Coverage News SentimentNeoleukin Therapeutics has a news sentiment score of 0.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Neoleukin Therapeutics this week, compared to 0 articles on an average week. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neoleukin Therapeutics insiders have bought 159,451.71% more of their company's stock than they have sold. Specifically, they have bought $1,305,133.00 in company stock and sold $818.00 in company stock.Percentage Held by InsidersOnly 1.58% of the stock of Neoleukin Therapeutics is held by insiders.Percentage Held by Institutions52.37% of the stock of Neoleukin Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Neoleukin Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neoleukin Therapeutics is -1.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeoleukin Therapeutics has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neoleukin Therapeutics (NASDAQ:NLTX) StockNeoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.Read More NLTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NLTX Stock News HeadlinesSeptember 26, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitSeptember 23, 2023 | americanbankingnews.comNeoleukin Therapeutics (NASDAQ:NLTX) Shares to Reverse Split on Monday, September 25thSeptember 28, 2023 | Weiss Ratings (Ad)Overlooked AI Stock Gets Urgent "Buy"We issued our first "Buy" rating on Apple when it traded at the equivalent of 56 cents per share. It's up 32,571% since. And while Nvidia is up 3x this year… We called it back in 2011. And it has surged 97x (9,624% to be exact) since then. Now, our Weiss Ratings has issued a "Buy" on a stock that's leading the AI revolution in one of the most profitable industries.September 22, 2023 | finance.yahoo.comNeoleukin Therapeutics Announces 1-for-5 Reverse Stock SplitAugust 18, 2023 | benzinga.comNeoleukin Therapeutics Recent Insider ActivityAugust 18, 2023 | finance.yahoo.comBAKER BROS. ADVISORS LP Reduces Stake in Neoleukin Therapeutics IncAugust 8, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMNB, CCF, NLTX, SCUAugust 1, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AJX, DEN, FREQ, NLTXSeptember 28, 2023 | Weiss Ratings (Ad)Guess What The Fed Is Doing To Your Money Now?For years, the Federal Reserve has been printing mountains of money jacking up interest rates and driving the U.S. into a recession. And just a few weeks ago, they did something even more disturbing. And hardly anyone is talking about it. Yet this could harm you more than money printing and interest rates. It made a frightening power grab of the U.S. dollar, and it could cause you to lose control of your cash.July 28, 2023 | finance.yahoo.comRedmile Group, LLC Boosts Stake in Neoleukin Therapeutics IncJuly 26, 2023 | benzinga.comMoore Kuehn Encourages AMNB, SCU, NLTX, and PRDS Investors to Contact Law FirmJuly 24, 2023 | 247wallst.comBaker Bros. Advisors Now Owns 19.99% of Neoleukin TherapeuticsJuly 19, 2023 | markets.businessinsider.comNeurogene, Neoleukin Announce Planned MergerJuly 18, 2023 | msn.comUniv. of Washington spinout Neoleukin Therapeutics merging with New York City startupJuly 18, 2023 | finanznachrichten.deNeoleukin Therapeutics, Inc.: Neurogene and Neoleukin Announce Definitive Merger AgreementJuly 18, 2023 | benzinga.comNeoleukin Therapeutics To Merge With Neurogene: Creates Biotech Firm Focused On Genetic Medicines For Neurological DiseasesJuly 18, 2023 | markets.businessinsider.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DEN, NLTX, FREQJuly 18, 2023 | msn.comNeoleukin jumps 7% on Neurogene mergerJuly 18, 2023 | marketwatch.comNeoleukin Therapeutics Shares Rise Premarket on Reverse Merger Deal >NLTXJuly 18, 2023 | technews.tmcnet.comNLTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Neoleukin Therapeutics, Inc. Is Fair to ShareholdersJuly 18, 2023 | finance.yahoo.comNeurogene and Neoleukin Announce Definitive Merger AgreementMay 23, 2023 | finance.yahoo.comBiomed Industries, Inc. Offers to acquire Neoleukin Therapeutics, Inc. (NASDAQ:NLTX)May 9, 2023 | markets.businessinsider.comMizuho Securities Reaffirms Their Hold Rating on Neoleukin Therapeutics (NLTX)April 7, 2023 | bizjournals.comNeoleukin Therapeutics promotes general counsel to interim CEOMarch 31, 2023 | seekingalpha.comNLTX Neoleukin Therapeutics, Inc.March 21, 2023 | markets.businessinsider.comNeoleukin Therapeutics (NLTX) Receives a Hold from Mizuho SecuritiesMarch 10, 2023 | finance.yahoo.comHere's Why We're Watching Neoleukin Therapeutics' (NASDAQ:NLTX) Cash Burn SituationSee More Headlines Receive NLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neoleukin Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NLTX Company Calendar Last Earnings8/10/2023Today9/28/2023Next Earnings (Estimated)11/13/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NLTX CUSIPN/A CIK1404644 Webwww.neoleukin.com Phone(866) 245-0312Fax778-331-4486Employees7Year FoundedN/APrice Target and Rating Average Stock Price Forecast$7.50 High Stock Price Forecast$7.50 Low Stock Price Forecast$7.50 Forecasted Upside/Downside+86.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($3.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-57,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-43.55% Return on Assets-36.13% Debt Debt-to-Equity RatioN/A Current Ratio17.17 Quick Ratio17.17 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$11.08 per share Price / Book0.36Miscellaneous Outstanding Shares8,800,000Free Float8,665,000Market Cap$35.46 million OptionableOptionable Beta1.17 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMs. Donna M. Cochener-Metcalfe J.D. (Age 48)Gen. Counsel, Interim CEO & Corp. Sec. Comp: $403.75kDr. David Baker M.D.Ph.D., Co-FounderMr. Sean Michael Smith (Age 37)Interim Chief Financial Officer Key CompetitorsZevra TherapeuticsNASDAQ:ZVRAXOMANASDAQ:XOMAMereo BioPharma GroupNASDAQ:MREOEmergent BioSolutionsNYSE:EBSVerrica PharmaceuticalsNASDAQ:VRCAView All CompetitorsInsiders & InstitutionsBros. Advisors Lp BakerBought 33,388 shares on 8/17/2023Total: $115,188.60 ($3.45/share)Bros. Advisors Lp BakerBought 377,760 shares on 8/15/2023Total: $1.19 M ($3.15/share)Western Standard LLCBought 860,882 shares on 8/15/2023Ownership: 1.956%Renaissance Technologies LLCBought 22,610 shares on 8/11/2023Ownership: 2.188%BlackRock Inc.Sold 80,527 shares on 8/11/2023Ownership: 1.130%View All Insider TransactionsView All Institutional Transactions NLTX Stock - Frequently Asked Questions Should I buy or sell Neoleukin Therapeutics stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neoleukin Therapeutics in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NLTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NLTX, but not buy additional shares or sell existing shares. View NLTX analyst ratings or view top-rated stocks. What is Neoleukin Therapeutics' stock price forecast for 2023? 5 Wall Street research analysts have issued 1 year target prices for Neoleukin Therapeutics' shares. Their NLTX share price forecasts range from $7.50 to $7.50. On average, they expect the company's stock price to reach $7.50 in the next twelve months. This suggests a possible upside of 86.1% from the stock's current price. View analysts price targets for NLTX or view top-rated stocks among Wall Street analysts. How have NLTX shares performed in 2023? Neoleukin Therapeutics' stock was trading at $2.5450 at the start of the year. Since then, NLTX shares have increased by 58.3% and is now trading at $4.03. View the best growth stocks for 2023 here. Are investors shorting Neoleukin Therapeutics? Neoleukin Therapeutics saw a decrease in short interest in the month of September. As of September 15th, there was short interest totaling 43,000 shares, a decrease of 63.5% from the August 31st total of 117,900 shares. Based on an average daily volume of 60,700 shares, the short-interest ratio is currently 0.7 days. Currently, 0.1% of the shares of the stock are sold short. View Neoleukin Therapeutics' Short Interest. When is Neoleukin Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023. View our NLTX earnings forecast. How were Neoleukin Therapeutics' earnings last quarter? Neoleukin Therapeutics, Inc. (NASDAQ:NLTX) posted its earnings results on Thursday, August, 10th. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.75) by $0.55. When did Neoleukin Therapeutics' stock split? Neoleukin Therapeutics's stock reverse split on the morning of Monday, September 25th 2023. The 1-5 reverse split was announced on Friday, September 22nd 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, September 22nd 2023. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of Neoleukin Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neoleukin Therapeutics investors own include Alibaba Group (BABA), Cisco Systems (CSCO), Pfizer (PFE), RTX (RTX), Procter & Gamble (PG), Sorrento Therapeutics (SRNE), CVS Health (CVS), Fulcrum Therapeutics (FULC) and Home Depot (HD). What is Neoleukin Therapeutics' stock symbol? Neoleukin Therapeutics trades on the NASDAQ under the ticker symbol "NLTX." Who are Neoleukin Therapeutics' major shareholders? Neoleukin Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (2.19%), Western Standard LLC (1.96%), BlackRock Inc. (1.13%) and Privium Fund Management B.V. (0.27%). Insiders that own company stock include Bros Advisors Lp Baker, Carl Walkey, Jonathan G Drachman, Priti Patel, Robert Ho and Sean Michael Smith. View institutional ownership trends. How do I buy shares of Neoleukin Therapeutics? Shares of NLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neoleukin Therapeutics' stock price today? One share of NLTX stock can currently be purchased for approximately $4.03. How much money does Neoleukin Therapeutics make? Neoleukin Therapeutics (NASDAQ:NLTX) has a market capitalization of $35.46 million. The company earns $-57,560,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. How can I contact Neoleukin Therapeutics? Neoleukin Therapeutics' mailing address is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. The official website for the company is www.neoleukin.com. The company can be reached via phone at (866) 245-0312, via email at investors@neoleukin.com, or via fax at 778-331-4486. This page (NASDAQ:NLTX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neoleukin Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.